The Spirit-HF-DZHK8 is a double‐blind, randomized, placebo‐controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo in reducing hospitalizations and death from heart failure with midrange or preserved ejection fraction. As a phase III study, it has the potential to change future treatment guidelines for diastolic heart failure.
